Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inspire Medical Systems achieves first profitable quarter, eyes international growth

Inspire Medical Systems reported a strong performance in Q4 2022, achieving its first profitable quarter and significant revenue growth. The company's focus on enhancing patient outcomes, expanding internationally, and optimizing operational efficiency positions it for continued success.
While challenges with the supply chain were addressed, the company needs to remain vigilant in managing disruptions and addressing analyst concerns to ensure sustained growth. Opportunities in product demand, market expansion, and operational enhancements offer avenues for further development.
Overall, Inspire Medical Systems' strategic initiatives, strong financial performance, and commitment to innovation indicate a positive outlook for future growth and market expansion. The company's focus on driving utilization, improving patient outcomes, and maintaining operational efficiency bodes well for its long-term success.

Inspire Medical Systems Inc reports stellar Q1 performance and eyes global growth opportunities

Inspire Medical Systems Inc delivered robust financial results in Q1 2023, driven by revenue growth and international expansion.
The company's strategic focus on innovation, customer engagement, and therapy adoption positions it well for future success.
Challenges in competition, operational efficiency, and market dynamics require careful navigation, but opportunities for growth and innovation abound.
Overall, Inspire's performance reflects a company poised for continued expansion and impact in the medical technology sector.

Inspire Medical Systems reports robust Q2 growth and eyes global expansion

Inspire Medical Systems delivered strong financial performance in Q2, with revenue growth and margin improvement.
The company's strategic focus on expanding globally, enhancing operational efficiency, and product innovation positions it for future success.
While facing challenges in managing expenses and market mix, Inspire Medical Systems is well-positioned to capitalize on growth opportunities.
Overall, the company's performance, strengths, and strategic initiatives indicate a positive outlook for future growth and market expansion.

Inspire Medical Systems achieves record patient milestone and revenue growth

Inspire Medical Systems reported strong performance in Q3 2023, with notable revenue growth and patient milestones.
Despite challenges with prior authorizations and EU MDR approval delays, the company remains focused on growth and stakeholder value.
Opportunities for expansion with payers and new programs signal a positive outlook for future growth and market reach.
Efforts to streamline processes, educate centers, and drive efficiencies position the company for continued success in the sleep apnea treatment market.

Inspire Medical Systems posts robust Q4 results, eyes global expansion

Inspire Medical Systems reported strong Q4 performance, focusing on growth, profitability, and patient outcomes.
Challenges include market competition, revenue declines in certain regions, and securing reimbursements.
Opportunities lie in expanding utilization rates, market growth in Europe and Asia, and collaborations for increased patient flow.

Inspire Medical Systems Inc reports robust Q1 performance and growth outlook

Inspire Medical Systems Inc's Q1 2024 performance reflects strong revenue growth, improved net loss metrics, and a positive outlook for profitability and revenue expansion in 2024.
The company's strengths lie in its patient-centric approach, innovative product pipeline, and strategic growth initiatives, while challenges include financial performance, competitive landscape, and market penetration.
Opportunities abound in expanding patient qualification, market awareness, and operational efficiency, positioning Inspire for sustained growth and market leadership in the healthcare sector.

Inspire Medical Systems reports strong Q2 performance and growth outlook

Inspire Medical Systems demonstrated robust financial performance, marked by revenue growth and improved profitability.
Strategic initiatives to enhance patient experience and expand market reach position the company for sustained growth.
While facing challenges related to rising expenses, the company's focus on operational efficiency and growth opportunities remains strong.

Inspire Medical Systems reports strong Q3 earnings and growth outlook

Inspire Medical Systems Inc demonstrated robust financial performance in Q3 2024, with revenue and net income showing significant growth.
Despite challenges like revenue headwinds in Q4, the company's focus on innovation and capacity expansion presents growth opportunities.
The upcoming launch of the Inspire V system and efforts to streamline patient access highlight Inspire's commitment to driving future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) investors concerning the Company's possible violations of federal securities laws. On November 7, 2023, after the market closed, Inspire Medical reported disappointing earnings results for the third quarter of 2023, admitting that it had been tracking problems with its pilot Advisor Care “Acceleration Program,” not.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Inspire Medical Systems, Inc. (INSP) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 7, 2023, after the market closed, Inspire Medical reported disappointing earnings results for the third quarter of 2023, admitting that it had be.

The Law Offices of Frank R. Cruz Announces Investigation of Inspire Medical Systems, Inc. (INSP) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between May 3, 2023 and November 7, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 20, 2024. SO WHAT: If you purchased Inspire Medical securities d.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INSP

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Inspire Medical common stock between May 3, 2023 and November 7, 2023, both dates inclusive (the “Class P.

INSPIRE MEDICAL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Inspire Medical Systems, Inc. and Encourages Investors to Contact the Firm

Inspire (INSP) reported earnings 30 days ago. What's next for the stock?

Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

3 Reasons to Retain Inspire Medical (INSP) Stock for Now

Inspire Medical Systems, Inc. shares have dropped below their late 2020 levels despite a five-fold increase in sales. The company has seen impressive revenue growth, although coming down a bit amidst the law of large numbers. Although operating losses have decreased, more work is needed to improve profit margins and demonstrate operating leverage.

Inspire Medical Systems: Time To Wake Up

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.

Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag

Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President and Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities LLC Robert Marcus - JPMorgan Chase & Co. Lei Huang - Wells Fargo & Company Travis Steed - Bank of America Jonathan Block - Stifel Financial Corp. Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Companies Chris Pasquale - Nephron Research LLC David Rescott - Robert W. Baird & Co. Anthony Petrone - Mizuho Securities USA Mike Kratky - Leerink Partners LLC Mike Polark - Wolfe Research, LLC Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon.

Inspire Medical Systems, Inc. (INSP) Q3 2023 Earnings Call Transcript

Inspire Reports Year-over-Year Revenue Growth of 40% in the Third Quarter MINNEAPOLIS, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today reported financial results for the quarter ended September 30, 2023.

Inspire Medical Systems, Inc. Announces Third Quarter 2023 Financial Results and Updates 2023 Outlook

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Today, we take a deeper look at Inspire Medical Systems, Inc., a medical device manufacturer focused on solutions for obstructive sleep apnea. Despite stellar revenue growth and a rock-solid balance sheet, the stock has fallen more than 50% from recent highs this summer. Is it time to buy the dip in Inspire Medical Systems shares?  An analysis follows in the paragraphs below.

Inspire Medical Systems: Stock In A Deep Sleep Despite Stellar Sales Growth

Avantor Inc.

Catalent

Danaher

DexCom

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

ALISO VIEJO, Calif. , Oct. 23, 2023 /PRNewswire/ -- Neuros Medical, Inc., a medical device company behind an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, today announced that David Veino has been appointed President and Chief Executive Officer.

Neuros Medical, Inc. Names David Veino as President and CEO and Expands Board of Directors

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Intuitive Surgical

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2023 after the close of trading on Tuesday, November 7. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Third Quarter 2023 Financial Results on November 7, 2023

MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key events at the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings in Nashville, TN, September 29 through October 4.

Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings

Madrigal Pharmaceuticals

Tandem Diabetes Care

Shares of companies that treat everything from Type 2 diabetes to sleep apnea have been sinking since new weight-loss medications skyrocketed.

Medtech Makers Are the Real Losers From Obesity Drugs

MINNEAPOLIS, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 2023 Healthcare Conference on Wednesday, September 6, 2023.

Inspire Medical Systems, Inc. to Present at the Wells Fargo 2023 Healthcare Conference

Inspire Medical Systems has performed well in 2023 with its hyperglossal nerve stimulation design for sleep apnea sufferers. The company plans to release a version without a sensor lead in 2024, making the procedure even easier for physicians. Inspire is focused on creating high-quality software to improve the user experience and compete with cumbersome masks.

Inspire Medical Systems: Excellent Execution And Reset Valuation

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.

Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates

Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants John Block - Stifel Robbie Marcus - JPMorgan Travis Steed - Bank of America Adam Maeder - Piper Sandler Richard Newitter - Truist Securities Lei Huang - Wells Fargo Anthony Petrone - Mizuho Americas David Rescott - Baird Matthew Mishan - KeyBanc Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. My name is Dilem [ph], and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) Q2 2023 Earnings Call Transcript

Inspire Medical Systems (INSP) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.53 per share a year ago.

Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates

Inspire Reports Year-over-Year Revenue Growth of 65% in the Second Quarter Inspire Reports Year-over-Year Revenue Growth of 65% in the Second Quarter

Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook

Inspire Medical Systems has reported a significant 84% rise in Q1 2023 revenue, reaching $127.9 million, driven by its innovative treatments for Obstructive Sleep Apnea. The company has received FDA clearance for expanded indications of its Inspire therapy, broadening the range of patients who can access the treatment. Despite facing competition and adoption challenges, Inspire's financial strength, innovative product pipeline, and recent successes position it as a compelling investment opportunity in the OSA market.

News for Inspire Medical Systems Inc Stock (INSP)